OncoMatch/Clinical Trials/NCT06805617
A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers
Is NCT06805617 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Ivonescimab for salivary gland cancer.
Treatment: Ivonescimab — The goal of this study is to evaluate the efficacy and safety of Ivonescimab in participants with advanced, metastatic salivary gland cancers. The name of the study drug involved in this study is: -Ivonescimab (a type of antibody)
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: VEGFR tyrosine kinase inhibitor
except receipt of a prior oral VEGFR TKI
Cannot have received: anti-PD-1 therapy
except receipt of a prior ... anti-PD-1 therapy
Lab requirements
Blood counts
ANC ≥1000/mcL; Hemoglobin ≥8.5 g/dL (no transfusions within 7 days); Platelets ≥100,000/mcL
Kidney function
Creatinine within normal limits, or CrCl ≥50 mL/min using Cockcroft-Gault or eGFR ≥50 mL/min using CKD-EPI
Liver function
Serum total bilirubin (T-bili) ≤1.5× ULN; for patients with liver metastases or confirmed/suspected Gilbert syndrome, T-bili ≤3× ULN; AST and ALT ≤2.5× ULN; for patients with liver metastases, AST and ALT ≤5× ULN
Participant must have organ and marrow function as defined below within 14 days prior to study registration: ANC ≥1000/mcL; Hemoglobin ≥8.5 g/dL (with no blood transfusions within 7 days of start of therapy); Platelets ≥100,000/mcL; Liver function: Serum total bilirubin (T-bili) ≤1.5× ULN; for patients with liver metastases or confirmed/suspected Gilbert syndrome, T-bili ≤3× ULN; AST and ALT ≤2.5× ULN; for patients with liver metastases, AST and ALT ≤5× ULN; Creatinine Within normal limits, or Creatinine clearance (CrCl) ≥50 mL/min using the Cockcroft-Gault formula or estimated glomerular filtration rate (eGFR) value ≥50 mL/min using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (adjustment by BSA is not required for eGFR); Urine protein: Urine protein <2+ or 24-hour urine protein quantification <1.0 g; Coagulation:prothrombin time (PT) or international normalized ratio (INR) ≤1.5× ULN, and partial prothrombin time (PTT) or activated partial thromboplastin time (aPTT) ≤1.5× ULN (unless abnormalities are unrelated to coagulopathy or coagulation)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Brigham and Women's Hospital · Boston, Massachusetts
- Dana-Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify